Shareholders Equity and Capital Stock (Details 3) - USD ($) $ in Thousands |
3 Months Ended | |
|---|---|---|
Mar. 31, 2024 |
Dec. 31, 2023 |
|
| Number of RSUs | 641,910 | 641,910 |
| Weighted-Average Remaining contractual life (years) | 1 year 2 months 12 days | |
| Aggregate Intrinsic Value | $ 1,027,056 | |
| January 04, 2025 [Member] | ||
| Number of RSUs | 332,850 | |
| Weighted-Average Remaining contractual life (years) | 9 months 18 days | |
| Aggregate Intrinsic Value | $ 532,560 | |
| Redemption date | Jan. 04, 2025 | |
| December 07, 2025 [Member] | ||
| Number of RSUs | 309,060 | |
| Weighted-Average Remaining contractual life (years) | 1 year 8 months 12 days | |
| Aggregate Intrinsic Value | $ 494,496 | |
| Redemption date | Dec. 07, 2025 |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|